Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells.

Fiche publication

Date publication

octobre 2021

Journal

Cancer letters

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GASMAN Stéphane , Mme LOMAZZI Sandra , Pr MUTTER Didier , Dr GOUMON Yannick , Dr VITALE Nicolas , Dr ORY Stéphane

Tous les auteurs :
Streit L, Moog S, Hugel S, Rame M, Tanguy E, Andry V, Schmid HA, Brunaud L, Bihain F, Nominé-Criqui C, Goumon Y, Lacomme S, Lomazzi S, Vix M, Mutter D, Vitale N, Ory S, Gasman S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34637845

Résumé

Increasingly common, neuroendocrine tumors (NETs) are regarded nowadays as neoplasms potentially causing debilitating symptoms and life-threatening medical conditions. Pheochromocytoma is a NET that develops from chromaffin cells of the adrenal medulla, and is responsible for an excessive secretion of catecholamines. Consequently, patients have an increased risk for clinical symptoms such as hypertension, elevated stroke risk and various cardiovascular complications. Somatostatin analogues are among the main anti-secretory medical drugs used in current clinical practice in patient with NETs. However, their impact on pheochromocytoma-associated catecholamine hypersecretion remains incompletely explored. This study investigated the potential efficacy of octreotide and pasireotide (SOM230) on human tumor cells directly cultured from freshly resected pheochromocytomas using an implemented catecholamine secretion measurement by carbon fiber amperometry. SOM230 treatment efficiently inhibited nicotine-induced catecholamine secretion both in bovine chromaffin cells and in human tumor cells whereas octreotide had no effect. Moreover, SOM230 specifically decreased the number of exocytic events by impairing the stimulation-evoked calcium influx as well as the nicotinic receptor-activated inward current in human pheochromocytoma cells. Altogether, our findings indicate that SOM230 acts as an inhibitor of catecholamine secretion through a mechanism involving the nicotinic receptor and might be considered as a potential anti-secretory treatment for patients with pheochromocytoma.